January 13, 2022 7:46am
Literal translation, what's happening next? What's up?
Pre-open indications: 4 BUYs and 3 SELL
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.13% (+47 points), S&P futures are UP +0.07% (+3 points) and NASDAQ futures are UP +0.08% (+14 points)
U.S. stock futures were slightly positive during early trading on Thursday,
European markets were down and stuck in the mud
Asia-Pacific markets mostly fell after seeing gains despite a red-hot inflation report.
Economic Data Docket: initial jobless claims for the week ending Jan. 8 will be released at 8:30 a.m. Economists polled forecast 200,000 people filed for unemployment, down from the previous week’s 207,000.
Henry’omics:
The Dow rose 0.1%, the S&P 500 climbed 0.3%, the Nasdaq advanced 0.2% while the small-cap Russell 2000 sank 0.7% in Wednesday's stock market trading.
A short pause in the major indexes could be constructive. It would be unusual for stocks to race straight up. A little sideways action would let stocks repair themselves, while leaders could stand out. <IBD>
Markets will turn their attention to employment data today, with the Labor Department scheduled to release its latest figures on weekly jobless claims before market open. Consensus economist forecasts indicate new filings for unemployment insurance will tick-up slightly from the prior week but gold near pre-pandemic lows.
If you didn’t remember what happen Wednesday night and the last session of 2021’s close, you won’t be prepared for today’s session:
RegMed Investors’ (RMi) closing bell: “the cell and gene therapy sector went off the road and into a ditch, again. As I stated, “after being oversold, when will the overbought syndrome materialize – a kill-joy statement but, soon to be true as it is happening already” … https://www.regmedinvestors.com/articles/12255
Ebb and flow – January and Q1 to date:
- 1 neutral 5 negative and 2 positive closes
Companies in my headlights – It’s your decision; I provide an idea and context:
Probabilities versus aftermarket/pre-open share pricing indication moves:
BUY:
CRISPR Therapeutics (CRSP) closed down -$2.85 to $69.86 after Tuesday’s +$3.62 to $72.71, Monday’s +$1.43 to $69.09, Friday’s +$0.48 to $67.66 and last Thursday’s -$1.83 to $67.18 with a positive +$0.59 or +0.84% pre-open indication,
Editas Medicine (EDIT) closed down -$2.27 to $23.550 after Tuesday’s +$0.07 to $25.75, Monday’s +$0.56 to $25.70, Friday’s +$0.73 to $25.14 and last Thursday’s -$0.19 to $24.41 with a positive +$0.29 or +1.23% pre-open indication
Intellia Therapeutics (NTLA) closed down -$7.28 to $97.96 after Tuesday’s +$1.01 to $195.24 with a positive +0.04 or +0.04% pre-open indication.
Vericel (VCEL) closed down again -$2.33 to $36.25 after Tuesday’s -$0.36 to $38.58, Monday’s +$2.46 to $38.94, Friday’s -$1.96 to $36.448 and last Thursday’s $38.44 with a positive +$0.70 or +1.93% preopen indication.
SELL from BUY:
Mesoblast (MESO) closed up +$0.06 to $4.83 with a negative -$0.21 or -4.35% pre-open indication.
Maintaining SELL:
Biostage (OTCQB: BSTG) closed up +$0.77 to $3.97 after Tuesday’s +$0.87 to $3.20, Monday’s -$0.03 to $2.33 with 2,076 shares traded, Friday’s +$0.03 to $2.36 with 300 shares traded and last Thursday’s flat with 1,165 shares traded. Will the “pump and promote” i.e., continue to stimulate BUYING volume and share price appreciation? Notice how the shares traded with and without the manipulated share pricing by volume stimulation; just an example of a “House of Cards” – just a game of “fake it because they can’t make it? Trailing factor is a terminal and wronful death suit which their insurance company refused to cover or reimburse legal fees which hinders indemnification of partner and heightens liability of management and the company.
Fate Therapeutics (FATE) closed down -$2.49 to $45.05 with a negative -$0.40 or -0.89% pre-open indication.
The BOTTOM LINE: Wednesday, the sector hit resistance slipping further off Tuesday’s sector positive close and Monday’s neutral close while the Nasdaq elbowed higher on Wednesday
Sector equities remained under pressure as earnings season is right around the corner.
The “BUY” zone is still questionable but, there’s room for oversold movement, I am NOT changing my position, “Brace for more choppiness as we move further into the month and the beginning of Q4/21 Q4 and end-of-year numbers”.
- I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors
So, my bottom of the Bottom Line, Investors should be extremely cautious about adding any new exposure.
- RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
